The widely used antipsychotic drug, olanzapine (OLA) shows large interindividual variability in metabolic clearance. Although the role of the enzymes CYP1A2, CYP2D6 and UGT1A4 has been extensively explored, little is known about the in vivo role of flavincontaining monooxygenases (FMOs) catalyzing the N-oxidation of OLA in vitro. We investigated the influence of FMO1 and 3 polymorphisms on the steady state serum concentrations of OLA and its N-oxide metabolite in 379 patients. The upstream FMO1*6 was associated with increased dose-adjusted serum OLA concentrations (C/Ds; P ¼ 0.008), an effect further enhanced by FMO1rs7877C4T in smokers. The influence of FMO3 polymorphisms was limited to variability in OLA N-oxide. Homozygous carriers of FMO3rs2266780A4G (p.E308G) displayed 50% lower C/D of OLA N-oxide compared with subjects homo-or heterozygous for the A-variant (Po0.003). Our data support the role of FMO3 in the N-oxidation of OLA and implicate for the first time the contribution of FMO1 and its functional *6 variant in OLA disposition.
INTRODUCTION
Olanzapine (OLA) is one of the most widely prescribed antipsychotic drugs in the treatment of schizophrenia and bipolar disorders. 1 Its use is, however, frequently associated with metabolic side effects and weight gain, which reduce compliance and cause discontinuation of treatment. 1, 2 Both the clinical efficacy and risk of adverse effects are related to OLA exposure, [3] [4] [5] and a target serum concentration range of 20-80 ng ml À 1 has been proposed. 6 Extensive interindividual variation in serum OLA concentration at a given dose is consistently observed in routine therapeutic drug monitoring (TDM). [7] [8] [9] This variability is influenced by environmental and demographic factors. Female non-smokers are predisposed to elevated systemic exposure, whereas male smokers display reduced OLA concentrations. [7] [8] [9] Increased age and body weight have also been associated with increased OLA exposure. [7] [8] [9] Co-administration of CYP1A2 inhibitors or inducers results in considerable changes in systemic exposure compared with that in patients on OLA monotherapy, that is, 2-3-fold increase in fluvoxamine-treated patients 9 and 40-70% reduction in carbamazapine-treated patients. 7, 10 A significant decrease in plasma concentrations of OLA has also been reported during concurrent use of valproate. 11, 12 However, the mechanism behind this reduction still remains uncertain. All factors affecting serum drug concentrations will further influence drug exposure in the central nervous system as a strong correlation between serum and cerebrospinal fluid OLA concentrations has been recently shown by us. 13 OLA is extensively metabolized, predominantly through UGT1A4 (uridine diphosphate-glucuronosyltransferase 1A4)-mediated direct glucuronidation and via oxidative pathways catalyzed by CYP1A2, CYP2D6 and flavin-containing monooxygenases (FMOs). [14] [15] [16] [17] Two functional drug metabolic polymorphisms, UGT1A4 L48V and CYP1A2*1F, have been associated with reduced serum OLA concentrations, [18] [19] [20] [21] whereas no significant effect of CYP2D6 pheno-or genotypes on single-dose or multipledose kinetics of OLA has been reported. 13, 20, 22 Recently, one intronic marker located in CYP3A43 was identified as a significant predictor of high OLA clearance. 23 However, this marker is much more prevalent among African Americans than subjects of Caucasian origin. 23 Also, the role of CYP3A43 (and other CYP3A) enzymes in the metabolism of OLA has not been characterized.
Even though FMO3 has been implicated in vitro as one of the major enzymes catalyzing the metabolism of OLA (to N-oxide), 15 data on the role of FMOs on the disposition of OLA in vivo is scarce. FMO-mediated N-oxidation is considered to be only of minor importance as low levels of N-oxide metabolites can generally be detected in vivo. 24 The assessment of the quantitative role of N-oxidation is, however, complicated as N-oxides can be reduced back to the parent compound. 25 The FMO enzymes are characterized in vitro by high catalytic efficiency and abundant protein expression in organs of importance for drug metabolism, that is, FMO3 in the adult liver and FMO1 in the kidney and intestine. [26] [27] [28] Expression of FMOs in the human brain further suggests a potential relevance of FMOs in the central nervous system. 29 The FMO1 rs12720462 (FMO1*6) polymorphism has, in one study, been associated with an increased risk for brain tumor among children exposed to residential insecticides during childhood. 30 Two single nucleotide polymorphisms (SNPs; rs10912765 and rs7877) in the 3 0 untranslated region of the FMO1 gene have been associated with nicotine dependence, which is in line with S-nicotine being a substrate of FMO1. 31 Recently, we observed an association between OLA concentrations in cerebrospinal fluid and FMO1*6 together with FMO3 rs3754491 (FMO3 g.-2177 G4C) in patients treated with OLA as the only antipsychotic drug.
In the clinical pharmacogenetic studies reported so far, FMO3 variants with available functional data, the compound K158/G308 allele, p.V257M and g.-2177 G4C, have been the most frequently evaluated ones. 32 The aim of the present study was to further verify our earlier findings on the influence of FMO1 and FMO3 SNPs on OLA disposition and to search for additional markers within regulatory elements in the non-coding region of the FMO3 gene in a large OLA-treated patient cohort with steady state serum concentration data for OLA and its N-oxide metabolite.
MATERIALS AND METHODS

Patient samples
The study was based on serum OLA data available from routine TDM service conducted at the Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway, during the period July 2007-December 2010. 33 Criteria for inclusion were: (a) the time between the last drug intake and serum sampling was 10-30 h, (b) measured OLA serum concentrations above the lower limit of quantification, and (c) no concurrent use of drugs known to interact with OLA pharmacokinetics (for example, carbamazepine and fluvoxamine), except from valproate. In the requisition forms for TDM of OLA, information was asked about the dates of treatment initiation or last dose adjustment, time of last dose intake before sampling and time of sampling. This information was used to judge which samples fulfilled the criteria for steady state (defined to be achieved by 43 half-lives of OLA, that is, minimum 4-5 days) and trough value. OLA is usually taken once daily, but twice daily administration may also be applied. Dosing once or twice daily was unfortunately not registered in this study. We therefore included only samples taken 10-30 h after last drug intake. Furthermore, from our previous assessment of a kinetic model for OLA, the time interval between drug intake and blood sampling was not identified as a significant variable (P ¼ 0.4). 33 DNA samples for FMO genotype analysis and data on steady state serum concentrations of OLA could be retrieved for 379 patients (sampling time after last drug intake, median ¼ 13 h). The patients included were of Caucasian origin. Due to current biobank regulation, DNA samples for genotyping are stored for 10 years, whereas serum samples for drug concentration determination can only be stored for 3 months post analysis. Re-analysis to measure the OLA N-oxide metabolite was therefore only possible for a subgroup of 123 patients. Inclusion of the 123 patients for N-oxide measurement was thus not based on any selection criteria. DNA was extracted from peripheral blood leukocytes using E.Z.N.A Blood DNA Mini Kit (Omega Bio-tek, Norcross, GA, USA).
OLA and OLA N-oxide analysis Serum concentrations of OLA and OLA N-oxide were analyzed by a validated and certified ultraperformance liquid chromatography-mass spectrometry (UPLC-MS)/MS method developed for routine TDM analyses. Serum samples were prepared with protein precipitation using acetonitrile. Analysis was performed using an Acquity UPLC linked to a Micromass Quattro Premier Tandem MS detector (Waters, Milford, MA, USA). Chromatographic separation was achieved using an Acquity UPLC BEG shield RP18 column (1.7 mm 1.0 Â 100 m; Waters) with gradient elution at 40 1C with a mix of ammonium acetate buffer (pH ¼ 4.8) and acetonitrile (18-45%) as mobile phase. The retention times were 1.7 and 1.1 min for OLA and the OLA N-oxide metabolite, respectively. Detection with multiple reaction monitoring was performed at the following transitions: m/z 313-256 for OLA and m/z 329-213 for OLA N-oxide. Promazine was used as internal standard (m/z 285-212, retention time 2.30 min). Pure standards were obtained from the following suppliers: Eli Lilly and Company, IN, USA for OLA (purity 99.9%), Chiron AS, Trondheim, Norway for OLA N-oxide (purity 97.2%) and SigmaAldrich, St. Louis, MO, USA for promazine (purity 99.0%). The calibration curves were 10-800 nmol l À 1 for OLA and 2-20 nmol l À 1 for OLA N-oxide. Intra-and interassay accuracy and precision were o15% for both analytes at concentrations within the respective calibration curves.
Marker selection and genotyping SNP markers were selected for the genomic region of FMO3 plus 10 kb in 5 0 and 5 kb in 3 0 flanking regions (chr1:169316660-169358581) using the HapMap database (release No.28, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/ gbrowse/hapmap28_B36/). SNP genotype data was retrieved from the CEPH group (Utah residents with ancestry from Northern and Western Europe) excluding individuals with 450% missing genotypes. To reduce the number of SNP markers needed for genotyping, a subset of SNPs tagging nearby markers was selected using the Tagger function implemented in Haploview v4.2 with the following criteria: minor allele frequency (MAF) Z0.05, pairwise tagging with r 2 threshold at 0.8, force inclusion of five FMO3 SNPs previously reported with functional impact as well as a minimum distance between tagSNPs of 60 bp (base pair). The suitability of each selected marker to be designed as Illumina GoldenGate assay (Illumina , San Diego, CA, USA) 34 was assessed. Failed ones (Illumina design score o0.4) were replaced by equivalent markers in complete linkage disequilibrium (LD). A final set of 15 FMO3 SNP markers was genotyped using Illumina GoldenGate assays with BeadXpress readout at The SNP&SEQ Technology Platform, Uppsala, Sweden. The overall reproducibility in the genotype data was 100% based on 4% of duplicated genotypings. The SNP call rates were between 99.7% and 100% for the study cohort. Each SNP genotype cluster plot was manually evaluated.
FMO1 polymorphisms rs12720462, rs10912765 and rs7877 were identified as markers for FMO1 based on data from literature. 31, 35 As pair-wise LD is high between rs10912765 and rs7877 (r 2 
40.8),
31 the latter was chosen as tag marker for both. Validated TaqMan Genotyping Assays (C____31270820_10 for rs12720462 and C_____14532_30 for rs7877) were used in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), according to the guidelines of the manufacturer.
Statistics
MAF and the probability of deviation from Hardy-Weinberg equilibrium due to chance were calculated for all SNPs. LD, characterized by r 2 values, was determined for pair-wise combinations of SNPs and LD plots were generated using Haploview v4.2. Statistical analysis was performed using STATISTICA v.10 (StatSoft , Tulsa, OK, USA) and two-tailed Po0.05 was considered to be statistically significant. Serum OLA and OLA N-oxide concentrations were adjusted for daily dose (C/D, nmol l À 1 mg À 1 ). Degree of correlation between OLA C/D and OLA N-oxide C/D (n ¼ 123) was assessed using Spearman rank correlation test (coefficient: r). The subgroup of 123 patients was assessed for deviation from the whole study population regarding patient characteristics (that is, age, gender, smoking status and co-medication with valproate), MAFs and C/D of OLA, using Mann-Whitney test (for continuous variables) or Fisher's exact test (for categorical variables).
As both OLA C/Ds (n ¼ 379) and OLA N-oxide C/Ds (n ¼ 123) showed significant deviation from normal distribution (Shapiro-Wilk W test, Po0.0001 in both the cases), they were log-transformed to attain normality (Shapiro-Wilk W test, P40.2 in both the cases). For this patient population, four demographic variables, age, gender, smoking status and co-medication with valproate, were identified as significant covariates for C/Ds of OLA in the previous study. 33 Adjustment for these covariates (age as continuous variable and the others as categorical variables) was made in the multivariate analyses performed. Multiple linear regression analysis applying best-subset method (Mallow's cp as criterion) was used to identify the subset of FMO3 polymorphisms that best describes concentration variability. Analysis of variance was used to assess the two FMO1 polymorphisms. When more than five carriers were identified in each SNP genotype group, genotype effect (coded as 0, 1 or 2 based on the number of the minor allele) was analyzed. Otherwise, allele effect (coded as 0 or 1 for noncarrier or carrier of the minor allele) was evaluated instead. Upon testing the statistical significance of specific differences, Bonferroni test was used as post hoc analysis. The combined effect of the identified genetic and demographic covariates was assessed in the final regression models applying backward stepwise regression. The adjusted value of R 2 obtained from the linear model was regarded as a measure of the explained variability.
Ethics
The study was approved by the following Norwegian authorities: the Regional Committee for Medical and Health Research Ethics, the Privacy Ombudsman and the Investigational Review Board at Diakonhjemmet Hospital.
RESULTS
Characteristics of the 379 patients and the subgroup of 123 patients with concentration data on OLA N-oxide are given in Table 1 . The subgroup displayed lower median age than that of the whole study population (39 years vs 45 years, P ¼ 0.045) but showed no difference regarding gender, smoking habit, comedication with valproate, MAFs and C/D of OLA (P40.1 in all the cases). The serum OLA N-oxide level was on average 4% to that of OLA, with a range from 1% to 11%. Correlation between OLA and OLA N-oxide concentrations was moderately high (r ¼ 0.72; Po0.001). The frequencies of the SNPs genotyped are summarized in Table 2 . No significant differences in MAF were found between the cohorts of 379 and 123 patients. No deviation from Hardy-Weinberg equilibrium was shown except for FMO1 rs7877. As the quality of the genotype cluster plots was verified manually and the current study was not designed for disease association, FMO1 rs7877 was not excluded from subsequent analysis. Of the 15 FMO3 SNPs, complete pair-wise LD (r 2 ¼ 1.0) was observed between rs12404183 and rs3754491 as well as between rs1736554 and rs1736557 (p.V257M) (Supplementary Figure S1) . Two FMO3 SNPs, rs12404183 and rs1736554, were therefore excluded from association analysis. The two FMO1 SNPs displayed little pair-wise LD with each other or to any of the FMO3 SNPs (Supplementary Figure S1) . Figure 1 ). The reduced C/Ds associated with G/G carriers remained significant (F 1,117 ¼ 14.5; P ¼ 0.0002) after further adjustment for the non-genetic covariates (Table 3A) . The FMO3 rs2266780A4G polymorphism, smoking status and gender together explained 28% of the concentration variability observed for OLA N-oxide, 11% being attributed to the FMO3 SNP (Table 3A) . Co-medication with valproate and age were not identified as significant factors. None of the FMO1 polymorphisms showed any significant association with C/Ds of OLA N-oxide.
No significant association was found between any of the FMO3 SNPs and the C/Ds of OLA in the cohort of 379 patients. However, both variant alleles of FMO1, rs12720462A (FMO1*6, MAF 379 ¼ 0.11; F 1,375 ¼ 4.9; P ¼ 0.03) and rs7877T (MAF 379 ¼ 0.25; Figure 2 ). Furthermore, among carriers of both variant alleles, no significant effect of smoking on C/Ds of OLA was found (P post hoc ¼ 0.82), which is in contrast to the other groups where smokers consistently had lower OLA C/Ds than non-smokers (P post hoc o0.001 for all the three group comparisons) (Figure 2) .
Assessing the combined effect of FMO1 polymorphisms, age, gender, smoking status and co-medication with valproate on the variability in serum OLA C/Ds in multiple linear regression models, FMO1 rs12720462C4A (FMO1*6) remained a significant factor (F 1,368 ¼ 6.7; P ¼ 0.02), whereas FMO1rs7877C4T did not (F 1,368 ¼ 3.2; P ¼ 0.08). Aging and FMO1 rs12720462C4A were associated with increased serum OLA C/Ds and male gender, smoking and co-medication with valproate with decreased OLA C/ Ds (Table 3B ). Approximately 37% of the variability in serum OLA C/Ds in the study cohort (n ¼ 379) could be explained by the five factors, FMO1*6 accounting for 2% (Table 3B) .
DISCUSSION
The present study is, to our knowledge, the most comprehensive clinical pharmacogenetic study performed so far with respect to FMO polymorphisms. The influence of multiple FMO1 and FMO3 polymorphisms on steady state serum concentrations of OLA in 379 psychiatric patients as well as of OLA N-oxide in a subgroup of 123 patients was evaluated using a routine TDM-based material. FMO1 rs12720462C4A (FMO1*6) polymorphism was associated with elevated serum OLA C/D (Table 3B ). The finding is in line with our previous observation of increased OLA C/Ds in cerebrospinal fluid of OLA-treated patients 21 and consistent with the reported 2-3-fold reduction in promoter activity in vitro. 35 The SNP influence accounted for 2% of the C/D variation in our study cohort (Table 3B ). FMO1 is expressed in the intestine and kidneys but not in the adult human liver. 28 Our results therefore suggest an increased systemic (and central nervous system) exposure of OLA in FMO1*6 carriers, due to decreased intestinal first-pass metabolism catalyzed by FMO1. Whether renal metabolism contributes to systemic elimination of OLA remains speculative. Renal FMO1-catalyzed metabolism has been demonstrated for imipramine, a FMO1-selective substrate. Upon incubation of imipramine with human liver and kidney tissue, imipramine N-oxide was the only metabolite detected in the kidney, whereas the hepatic biotransformation of imipramine was attributed to reactions catalyzed by CYP450s, with no formation of N-oxide. 36 Renal expression of FMOs in rats and mice is concentrated in areas highly exposed to xenobiotics, where many other metabolizing enzymes are also found, namely proximal and distal tubules of the renal cortex. 37 Additional support for the involvement of FMO1 in OLA metabolic clearance was observed among FMO1*6 carriers who also carried the FMO1 rs7877T variant. The well-characterized influence of smoking on C/D of OLA was not seen among patients with both variant FMO alleles (rs12720562A and rs7877T) while the effect of smoking was significant in the other genotype groups Figure 1 . Dose-adjusted serum olanzapine N-oxide concentrations (C/D OLA N-oxide) in 123 OLA-treated patients stratified by FMO3 rs2266780 A4G (p.E308G). Genotype composition and sample size are given for each subgroup. The median concentrations with interquartile range are shown both numerically (raw data) and graphically (log-transformed). Non-outlier range is also displayed by whiskers in the boxplot. Comparisons to G/G genotype are denoted by P-values (Bonferroni test). FMO polymorphisms and olanzapine pharmacokinetics MM Sö derberg et al ( Figure 2 ). Moreover, among smokers, the same group had significantly higher OLA C/Ds than patients homozygous for the wild-type variant of these alleles (C/C and C/C) ( Figure 2 ). These findings suggest a reduced influence of smoking on OLA clearance in patients carrying both rs12720562A and rs7877T. FMO1 has been shown to be an efficient catalyst of nicotine N-oxidation and the FMO1rs7877C4T polymorphism was originally identified as a determinant for maintenance of nicotine addiction. 31 The reported odds ratio of 0.77 for heavy smoking associated with FMO1rs7877C4T suggests a prolonged duration of nicotine effect. 31 A hypothetical explanation for our observations could be that if carriers of this polymorphism smoke less heavily, there would also be lower induction of drug metabolic enzymes such as CYP1A2, resulting in higher than expected OLA C/Ds. The significant influence of FMO3 rs2266780G (p.E308G) on the OLA N-oxide C/D is in line with the role of FMO3 as an enzyme catalyzing the N-oxidation of OLA. Patients homozygous for the FMO3 rs2266780G variant had approximately 50% lower serum C/ D of OLA N-oxide compared with those of the other two genotype groups (Figure 1 ). About 11% of the C/D variation observed for OLA N-oxide can be attributed to this FMO3 SNP (Table 3A) . However, no effect of FMO3 polymorphisms on the C/D of OLA was found. The levels of OLA N-oxide detected in patient serum were low, ranging from 1% to 11% to those of OLA with an average of 4% (Table 1) . This is in accordance with a minor quantitative role of this metabolic pathway for the elimination of OLA in man. 16 Interestingly, however, rapid reduction of N-oxide metabolites back to the corresponding tertiary amines is known to take place simultaneously with N-oxidation, as observed in liver preparations and in blood. 25 Although, to our knowledge, there are no studies with respect to OLA specifically, this cyclic interconversion between the parent compound and its N-oxide has been experimentally confirmed for several tertiary amines such as clozapine, imipramine, chlorpromazine, trimethylamine and tamoxifen. 24, 38, 39 We observed a relatively high correlation between the serum concentrations of OLA N-oxide and the parent compound (r ¼ 0.72, Po0.001), which could suggest an equilibrium between them. If one takes N-oxide reduction into consideration, the low level of OLA N-oxide detected in patient serum would seem less contradictory to the significant influence associated with FMO SNPs observed herein and to the markedly high catalytic efficiency of FMO-mediated oxidation of OLA in vitro.
15
In vivo assessment on pharmacological activity of OLA N-oxide has been limitedly reported. In one early study available, four major OLA metabolites, including N-oxide, were shown to be considerably less active than the parent compound and their contribution to the pharmacological profile of OLA was concluded to be unlikely. 40 However, the more recently developed method using knockout mouse lines may provide new insights on the role of the N-oxide metabolites. For imipramine, its N-oxide metabolite is suggested to be associated with sedation, as the effect was evident in the wild-type mice but not seen in FMO1 knockout mice. 41 Similar assessment for OLA is warranted to elucidate the potential pharmacological relevance of the OLA N-oxide metabolite. Moreover, N-oxide metabolite is highly hydrophilic. Once formed in the brain, the passage of N-oxide through brainblood-barrier would thus be expected to be limited. The N-oxide metabolite may, in theory, function as reservoir for the parent compound and prolong the effect duration due to the cyclic interconversion. As the extent of OLA N-oxide metabolite formation in the brain is unknown, this also presents a relevant aspect for future investigation.
FMO3 rs2266780A4G forms part of the compound allele K158/ G308 that is associated with variable degrees of reduced enzyme activity depending on substrates tested. [42] [43] [44] As expected, all the homozygous carriers of FMO3 rs2266780G (p.E308G) herein were also homozygous for FMO3 rs2266782A (p.E158K; data not shown). None of the other FMO3 variants studied showed any influence on the C/Ds of either OLA or OLA N-oxide, despite the large genomic region tagged. Most of the known functional variants, mainly rare nonsense and missense mutations, have been uncovered while studying patients with trimethylaminuria (severely impaired or abolished FMO3 metabolic capacity, also known as the fish-odour syndrome). 45 Few FMO3 SNP markers have been identified during the course of assessing interindividual variation in enzyme activity observed within the general population. 45 One study reported the interindividual variability in FMO3 gene expression and protein content to be significantly correlated to the levels of transcription regulatory factors like HNF4 but not affected by FMO3 haplotypes. 46 Our results indirectly point towards the need of incorporating trans-acting factors into future studies. However, this approach is challenging as FMO3 regulation is exceptionally complex and poorly characterized. 47 Based on our findings and published data on the four major OLA metabolic pathways, CYP1A2 together with FMO seem to be most relevant to the total OLA clearance. Significant correlation between the plasma ratio of the CYP1A2-mediated metabolite desmethyl OLA to OLA and OLA clearance has been documented 17 as well as influence by CYP1A2*1F on serum OLA C/Ds.
19
CYP2D6 polymorphisms were early on precluded as major contributors to interindividual variability in OLA metabolism. 20, 22 Although direct glucuronidation by UGTs is considered to be the primary route of OLA biotransformation due to the large amount of OLA N-glucuronides detected in plasma, fecal and urinary samples, 16 inconsistent results have been reported for the effect of UGT1A4*3 on systemic OLA exposure. 18, 21, 33, 48 The recent assessment, both in vitro and in vivo, found the SNP effect to be only apparent on formation of the N-glucuronide metabolite but cause no alteration in serum C/Ds of OLA. 33 Identification of novel genetic markers of UGT1A4 are warranted in future studies for clarifying the importance of UGT1A4 in OLA metabolism. Except from valproate users, patients treated with drugs known to interact with OLA pharmacokinetics were excluded from our study. Recent studies by Bergemann et al. 11 and Spina et al. 12 have reported significantly lower serum concentration of OLA during concurrent use of valproate, but the mechanism behind the interaction is still unknown. In the present study, we also observed significantly lower OLA levels in patients co-medicated with valproate, which further supports the relevance of this interaction. As N-oxide levels were unaffected by valproate use (Table 3A) , the interaction mechanism is unlikely to involve induction of FMO enzymes. Thus, further studies are required to outline the mechanism behind the reducing effect of valproate on OLA serum concentrations.
There are some methodological limitations associated with the use of naturalistic TDM data in pharmacokinetic research. These include potential deviation from steady state conditions, potential compliance problems and other factors such as unreported comedication with drugs or herbal agents, which all may affect C/D ratios of parent drug and metabolites. However, TDM studies allow the inclusion of larger data samples, which often outweigh these limitations.
In summary, two common FMO1 polymorphisms, rs12720462C4A and rs7877C4T, were associated with increased steady state serum OLA exposure among smokers, whereas no significant influence of FMO3 SNPs was recognized. The mechanism of the FMO1-associated influence on OLA metabolic clearance needs to be further clarified but could be explained by reduced FMO1-catalyzed first-pass metabolism of OLA in the intestine. OLA N-oxide levels were, in most patients, o10% to those of the parent compound. The significant influence of FMO3 rs2266780A4G (p.E308G) on the C/D of OLA N-oxide supports the impact of this variant on FMO3 enzyme activity and the role of the FMO3 enzyme on OLA N-oxidation in vivo. The polymorphisms evaluated herein, however, contribute only to limited extent to the overall variability in OLA metabolism at maintenance treatment at population level. Nevertheless, they might still be relevant for individuals who harbor undesirable combinations of multiple determinants with small influence per se.
